Insmed Incorporated (NASDAQ:INSM) Position Cut by Fiera Capital Corp

Fiera Capital Corp lowered its position in shares of Insmed Incorporated (NASDAQ:INSM) by 2.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 592,415 shares of the biopharmaceutical company’s stock after selling 13,112 shares during the period. Fiera Capital Corp owned 0.34% of Insmed worth $43,246,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. SG Americas Securities LLC increased its stake in shares of Insmed by 123.1% in the first quarter. SG Americas Securities LLC now owns 8,508 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 4,695 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in Insmed during the 1st quarter valued at $4,515,000. Headlands Technologies LLC acquired a new position in Insmed during the 1st quarter worth $59,000. Russell Investments Group Ltd. grew its stake in shares of Insmed by 15,915.2% in the first quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 21,963 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Insmed by 10.0% in the first quarter. ProShare Advisors LLC now owns 35,241 shares of the biopharmaceutical company’s stock worth $956,000 after purchasing an additional 3,218 shares in the last quarter.

Insider Buying and Selling

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,882 shares of company stock valued at $5,765,446. Corporate insiders own 4.60% of the company’s stock.

Insmed Trading Up 0.6 %

Shares of INSM stock traded up $0.41 during trading hours on Friday, reaching $72.10. 233,293 shares of the stock traded hands, compared to its average volume of 2,255,116. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $12.90 billion, a PE ratio of -12.89 and a beta of 1.12. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $80.53. The business has a fifty day moving average price of $72.57 and a 200 day moving average price of $62.52.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $93.36 million. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.10) earnings per share. On average, equities research analysts forecast that Insmed Incorporated will post -5.52 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on INSM shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Monday, September 9th. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Thursday, October 3rd. TD Cowen boosted their target price on Insmed from $75.00 to $98.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Morgan Stanley increased their price target on Insmed from $60.00 to $85.00 and gave the company an “overweight” rating in a research note on Friday, July 12th. Finally, Stifel Nicolaus boosted their price objective on Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $83.07.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.